Current Report Filing (8-k)
21 January 2023 - 9:02AM
Edgar (US Regulatory)
0001497504
false
0001497504
2023-01-14
2023-01-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
January 14, 2023
PLx Pharma Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware |
|
001-36351 |
|
46-4995704 |
| (State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
| 9 Fishers Lane, Suite E, Sparta, New Jersey |
|
07871 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (973) 409-6541
| |
| (Former name or former address if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the follow provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol |
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
PLXP |
The NASDAQ Capital Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
On January 19, 2023, John W. Hadden II, a member
of the Board of Directors (the “Board”) of PLx Pharma, Inc. (the “Company”), resigned from the Board effective
immediately. Mr. Hadden’s resignation is not the result of any disagreement with the Company.
In August 2022, and as previously disclosed, the
Company engaged Raymond James & Associates, Inc. as financial advisor to evaluate strategic alternatives to maximize stockholder value.
On January 14, 2023, the Company engaged SierraConstellation Partners LLC, a business advisory firm, to further explore strategic alternatives,
which may include a liquidation strategy in the event that more advantageous alternatives prove unavailable to the Company.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| | Exhibit No. | Description |
| | | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
PLX PHARMA INC. |
|
| |
|
|
| |
|
|
|
|
| Dated: January 20, 2023 |
By: |
/s/ Natasha Giordano |
|
| |
|
Name: |
Natasha Giordano |
|
| |
|
Title: |
President and Chief Executive Officer |
|
EXHIBIT INDEX
| | Exhibit No. | Description |
| | | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024
